Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

IDXG - Interpace Biosciences Inc


Previous close
1.5
0   0%

Share volume: 200
Last Updated: Thu 29 Aug 2024 06:00:00 AM CEST

PREVIOUS CLOSE
CHG
CHG%

$1.50
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Company vs Stock growth
vs
Performance
5 Days
-12.65%
1 Month
20.83%
3 Months
0.21%
6 Months
31.82%
1 Year
31.94%
2 Year
-17.14%
Key data
Stock price
$1.50
P/E Ratio 
-0.20
DAY RANGE
N/A - N/A
EPS 
-$8.15
52 WEEK RANGE
$0.78 - $2.60
52 WEEK CHANGE
$0.38
MARKET CAP 
6.363 M
YIELD 
N/A
SHARES OUTSTANDING 
4.388 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$9,442
AVERAGE 30 VOLUME 
$10,774
Company detail
CEO: Jack Stover
Region: US
Website: https://www.interpacediagnostics.com/
Employees: 104
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry:
Sector:

advancing patient care through molecular diagnostic testing. interpace diagnostics develops molecular diagnostic tests. our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. you can be assured that all of the molecular tests we offer are driven by rigorous, validated science. we power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. the unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.

Recent news